^
Contact us to learn more about
our Premium Content: News alerts, weekly reports and conference plannersDRUG:
NILK-2301
i
Other names: NILK-2301, NI-2301, NI 2301, NILK 2301
Contact us to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Company:
LamKap Bio, Light Chain Biosci
Drug class:
CD3 agonist, CEACAM5 inhibitor
Related drugs:
5ms
Development and characterization of NILK-2301, a novel CEACAM5xCD3 κλ bispecific antibody for immunotherapy of CEACAM5-expressing cancers. (PubMed, J Hematol Oncol)
In summary, NILK-2301 combines promising preclinical activity and safety with lower probability of ADA-generation due to its format compared to other molecules and is scheduled to enter clinical testing at the end of 2023.
Journal • IO biomarker
|
CEACAM5 (CEA Cell Adhesion Molecule 5)
|
CEACAM5 expression • CEACAM5 positive
|
NILK-2301
almost2years
Novel CEAxCD3 (NILK-2301) and CEAxCD28 (NILK-3301) κλ bispecific antibodies for next generation immunotherapy of CEA-expressing cancer (ESMO 2022)
NILK-2301 + NILK-3301 combination treatment significantly increases activity already at low NILK-2301 doses with reduced cytokine release when given sequentially. IND-filing for NILK-2301 is expected in Q4/2022.
IO biomarker
|
CD8 (cluster of differentiation 8) • IFNG (Interferon, gamma) • IL6 (Interleukin 6) • TNFA (Tumor Necrosis Factor-Alpha) • CEACAM5 (CEA Cell Adhesion Molecule 5) • IL2RA (Interleukin 2 receptor, alpha) • CD4 (CD4 Molecule) • IL2 (Interleukin 2)
|
CEACAM5 expression • IL2RA expression • CEACAM5 positive • CD4 expression
|
NILK-2301 • NILK-3301
Share via
